Trump Warns China Against ‘Substantial’ Retaliation in Trade War
(Bloomberg) -- President Donald Trump warned China against “substantial” retaliation for new U.S. tariffs after his escalating trade war with Beijing rocked global financial markets.
“There can be some retaliation but it can't be very substantial,” Trump told reporters on Monday during a meeting with Hungarian Prime Minister Viktor Orban.
China on Monday announced plans to raise duties on some American imports starting June 1, defying Trump's warning to resist escalating the trade war. Beijing's move sent stocks tumbling and clouded the outlook for the global economy.
Trump predicted China would attempt to target U.S. farmers, a mainstay of the president's political support. Farmers “will make the same kind of money” even if they face retaliation, he said.
The two nations reached a stalemate Friday in trade talks that the White House had expected to conclude this month with a deal.
China's move to hike tariffs came in response to the U.S.'s decision last week to increase levies on $200 billion in Chinese imports to 25% from 10%. Trump on Monday accused China of backing out of a tentative deal, saying Beijing reneged on an agreement to enshrine a wide range of reforms in Chinese law.
U.S. stocks and commodities tumbled after China's retaliation. More than 450 stocks in the the S&P 500 fell and the Dow Jones Industrial Average slumped over 600 points after China targeted some of the nation's biggest exporters.
--With assistance from Jennifer Jacobs.
To contact the reporter on this story: Margaret Talev in Washington at mtalev@bloomberg.net
To contact the editors responsible for this story: Alex Wayne at awayne3@bloomberg.net, Joshua Gallu
©2019 Bloomberg L.P.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.